Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT07382960

Pramipexole and the Risk of Serious Adverse Events

Conditions: Older Adults (65 Years and Older), Chronic Kidney Disease (CKD)

Sex: All

Ages: 66 Years – N/A

Healthy volunteers: No

Enrollment: 1100

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Location: London Health Sciences Centre Research Institute London Ontario

Summary

This is a population-based cohort study assessing whether initiation of a higher dose of pramipexole (0.25 or 0.375 mg/day), compared with a lower dose (0.125 mg/day), in older adults with advanced chronic kidney disease (CKD) (an estimated glomerular filtration rate \[eGFR\] \

Eligibility Criteria

Inclusion Criteria: The cohort will include older adults aged 66 years or older with advanced CKD (an eGFR \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07382960). StuddyBuddy aggregates publicly available trial information.